• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多囊肾病的代谢观点病理生物学。

The pathobiology of polycystic kidney disease from a metabolic viewpoint.

机构信息

National Institutes of Health, Kidney Disease Branch/National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, USA.

出版信息

Nat Rev Nephrol. 2019 Dec;15(12):735-749. doi: 10.1038/s41581-019-0183-y. Epub 2019 Sep 5.

DOI:10.1038/s41581-019-0183-y
PMID:31488901
Abstract

Autosomal dominant polycystic kidney disease (ADPKD) affects an estimated 1 in 1,000 people and slowly progresses to end-stage renal disease (ESRD) in about half of these individuals. Tolvaptan, a vasopressin 2 receptor blocker, has been approved by regulatory authorities in many countries as a therapy to slow cyst growth, but additional treatments that target dysregulated signalling pathways in cystic kidney and liver are needed. Metabolic reprogramming is a prominent feature of cystic cells and a potentially important contributor to the pathophysiology of ADPKD. A number of pathways previously implicated in the pathogenesis of the disease, such as dysregulated mTOR and primary ciliary signalling, have roles in metabolic regulation and may exert their effects through this mechanism. Some of these pathways are amenable to manipulation through dietary modifications or drug therapies. Studies suggest that polycystin-1 and polycystin-2, which are encoded by PKD1 and PKD2, respectively (the genes that are mutated in >99% of patients with ADPKD), may in part affect cellular metabolism through direct effects on mitochondrial function. Mitochondrial dysfunction could alter the redox state and cellular levels of acetyl-CoA, resulting in altered histone acetylation, gene expression, cytoskeletal architecture and response to cellular stress, and in an immunological response that further promotes cyst growth and fibrosis.

摘要

常染色体显性多囊肾病(ADPKD)影响估计每 1000 人中就有 1 人,并且在这些人中约有一半会缓慢进展为终末期肾病(ESRD)。加压素 2 型受体阻滞剂托伐普坦已被许多国家的监管机构批准用于减缓囊肿生长,但需要针对囊性肾脏和肝脏中失调信号通路的其他治疗方法。代谢重编程是囊性细胞的一个显著特征,也是 ADPKD 病理生理学的一个潜在重要因素。以前涉及疾病发病机制的许多途径,如失调的 mTOR 和原发性纤毛信号,在代谢调节中起作用,并且可能通过这种机制发挥作用。其中一些途径可以通过饮食改变或药物治疗来进行操作。研究表明,多囊蛋白-1 和多囊蛋白-2 分别由 PKD1 和 PKD2 编码(ADPKD 患者中 >99%的突变基因),可能通过直接影响线粒体功能部分影响细胞代谢。线粒体功能障碍可能会改变氧化还原状态和细胞内乙酰辅酶 A 水平,导致组蛋白乙酰化、基因表达、细胞骨架结构和对细胞应激的反应改变,并引起免疫反应,从而进一步促进囊肿生长和纤维化。

相似文献

1
The pathobiology of polycystic kidney disease from a metabolic viewpoint.多囊肾病的代谢观点病理生物学。
Nat Rev Nephrol. 2019 Dec;15(12):735-749. doi: 10.1038/s41581-019-0183-y. Epub 2019 Sep 5.
2
NHA2 promotes cyst development in an in vitro model of polycystic kidney disease.NHA2 促进了多囊肾病体外模型中的囊肿发育。
J Physiol. 2019 Jan;597(2):499-519. doi: 10.1113/JP276796. Epub 2018 Oct 17.
3
Clinical Manifestation and Management of ADPKD in Western Countries.西方国家常染色体显性多囊肾病的临床表现与治疗
Kidney Dis (Basel). 2016 Oct;2(3):120-127. doi: 10.1159/000449394. Epub 2016 Oct 6.
4
Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease.运用系统生物学方法鉴定多囊肾病进展过程中的转录组重编程及候选微小RNA靶点。
BMC Syst Biol. 2011 Apr 25;5:56. doi: 10.1186/1752-0509-5-56.
5
Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease.通过靶向鞭毛内运输88蛋白进行纤毛长度的基因降低可阻碍常染色体显性多囊肾病小鼠模型中的肾和肝囊肿形成。
Kidney Int. 2020 Nov;98(5):1225-1241. doi: 10.1016/j.kint.2020.05.049. Epub 2020 Jun 28.
6
Identification of pathological transcription in autosomal dominant polycystic kidney disease epithelia.常染色体显性多囊肾病上皮细胞中的病理性转录鉴定。
Sci Rep. 2021 Jul 23;11(1):15139. doi: 10.1038/s41598-021-94442-8.
7
Polycystin-1: a master regulator of intersecting cystic pathways.多囊蛋白-1:交叉性囊性通路的主要调节因子。
Trends Mol Med. 2014 May;20(5):251-60. doi: 10.1016/j.molmed.2014.01.004. Epub 2014 Jan 31.
8
Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.常染色体显性遗传性多囊肾病与吡格列酮治疗:全面综述,重点介绍分子发病机制和药理学方面。
Mol Med. 2020 Dec 11;26(1):128. doi: 10.1186/s10020-020-00246-3.
9
The cellular pathways and potential therapeutics of Polycystic Kidney Disease.多囊肾病的细胞途径和潜在治疗方法。
Biochem Soc Trans. 2021 Jun 30;49(3):1171-1188. doi: 10.1042/BST20200757.
10
The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.主调控因子 Myc 和 p53 在多囊肾病中的细胞信号转导和功能。
Cell Signal. 2020 Jul;71:109594. doi: 10.1016/j.cellsig.2020.109594. Epub 2020 Mar 4.

引用本文的文献

1
Mechanistic Insights into the Pathogenesis of Polycystic Kidney Disease.多囊肾病发病机制的机制性见解
Cells. 2025 Aug 5;14(15):1203. doi: 10.3390/cells14151203.
2
Microvascular aberrations found in human polycystic kidneys are an early feature in a Pkd1 mutant mouse model.在人类多囊肾中发现的微血管异常是Pkd1突变小鼠模型中的一个早期特征。
Dis Model Mech. 2025 Apr 1;18(4). doi: 10.1242/dmm.052024. Epub 2025 Apr 28.
3
Physiologic mechanisms underlying polycystic kidney disease.多囊肾病的生理机制。

本文引用的文献

1
Polycystin 2 regulates mitochondrial Ca signaling, bioenergetics, and dynamics through mitofusin 2.多囊蛋白 2 通过线粒体融合蛋白 2 调节线粒体钙信号、生物能量和动力学。
Sci Signal. 2019 May 7;12(580):eaat7397. doi: 10.1126/scisignal.aat7397.
2
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.奥曲肽长效释放剂治疗晚期常染色体显性遗传多囊肾病(ALADIN 2):一项随机、双盲、安慰剂对照、多中心试验。
PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.
3
Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways.
Physiol Rev. 2025 Jul 1;105(3):1553-1607. doi: 10.1152/physrev.00018.2024. Epub 2025 Feb 12.
4
GLIS3: A novel transcriptional regulator of mitochondrial functions and metabolic reprogramming in postnatal kidney and polycystic kidney disease.GLIS3:出生后肾脏及多囊肾病中线粒体功能和代谢重编程的新型转录调节因子。
Mol Metab. 2024 Dec;90:102052. doi: 10.1016/j.molmet.2024.102052. Epub 2024 Nov 5.
5
Multiomics profiling of mouse polycystic kidney disease progression at a single-cell resolution.单细胞分辨率下的小鼠多囊肾病进展的多组学分析。
Proc Natl Acad Sci U S A. 2024 Oct 22;121(43):e2410830121. doi: 10.1073/pnas.2410830121. Epub 2024 Oct 15.
6
Genetic and radiological aspects of pediatric renal cystic disease: A case series.小儿肾囊性疾病的遗传和放射学方面:病例系列。
Biomedica. 2024 May 31;44(Sp. 1):27-41. doi: 10.7705/biomedica.7110.
7
Reprogramming of Energy Metabolism in Human Polycystic Kidney Disease: A Systems Biology Analysis.人类多囊肾病中能量代谢的重编程:系统生物学分析。
Int J Mol Sci. 2024 Jun 29;25(13):7173. doi: 10.3390/ijms25137173.
8
Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease.肌球蛋白相关转录因子在多囊肾病中介导上皮纤维化。
Cells. 2024 Jun 5;13(11):984. doi: 10.3390/cells13110984.
9
Gene regulatory networks in disease and ageing.疾病和衰老中的基因调控网络。
Nat Rev Nephrol. 2024 Sep;20(9):616-633. doi: 10.1038/s41581-024-00849-7. Epub 2024 Jun 12.
10
Multi-omics profiling of mouse polycystic kidney disease progression at a single cell resolution.以单细胞分辨率对小鼠多囊肾病进展进行多组学分析。
bioRxiv. 2024 May 31:2024.05.27.595830. doi: 10.1101/2024.05.27.595830.
多囊肾病中代谢重编程的剖析揭示了生物能量途径的协同重塑。
Commun Biol. 2018 Nov 16;1:194. doi: 10.1038/s42003-018-0200-x. eCollection 2018.
4
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.兰瑞肽对常染色体显性多囊肾病患者肾功能的影响:DIPAK 1 随机临床试验。
JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.
5
Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease.Mcp1 促进常染色体显性多囊肾病中巨噬细胞依赖性囊肿扩张。
J Am Soc Nephrol. 2018 Oct;29(10):2471-2481. doi: 10.1681/ASN.2018050518. Epub 2018 Sep 12.
6
Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.同位素示踪技术在人肾透明细胞癌中的应用表明,肿瘤组织在体内葡萄糖氧化受到抑制。
Cell Metab. 2018 Nov 6;28(5):793-800.e2. doi: 10.1016/j.cmet.2018.07.020. Epub 2018 Aug 23.
7
Metabolism and mitochondria in polycystic kidney disease research and therapy.多囊肾病的研究与治疗中的代谢和线粒体。
Nat Rev Nephrol. 2018 Nov;14(11):678-687. doi: 10.1038/s41581-018-0051-1.
8
Mitochondrial fidelity and metabolic agility control immune cell fate and function.线粒体保真度和代谢灵活性控制免疫细胞的命运和功能。
J Clin Invest. 2018 Aug 31;128(9):3651-3661. doi: 10.1172/JCI120845. Epub 2018 Jul 30.
9
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗常染色体显性遗传多囊肾病的长期疗效观察。
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.
10
Molecular Actions of PPARα in Lipid Metabolism and Inflammation.PPARα 在脂质代谢和炎症中的分子作用。
Endocr Rev. 2018 Oct 1;39(5):760-802. doi: 10.1210/er.2018-00064.